LPMX-1 is under clinical development by LipoMedix Pharmaceutical and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect LPMX-1’s likelihood of approval (LoA) and phase transition for Bile Duct Cancer (Cholangiocarcinoma) took place on 31 May 2021, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their LPMX-1 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

LPMX-1 overview

LPMX-1 (Promitil, PL-MLP) is under development for the treatment of solid tumors including metastatic colorectal cancer, adenocarcinoma of the gastroesophageal junction, hepatocellular carcinoma, bile duct cancer (cholangiocarcinoma), gastric cancer, gallbladder cancer, rectal cancer, esophageal cancer, exocrine pancreatic cancer. The drug candidate is a new chemical entity prodrug of mitomycin-C administered through intravenous route. Mitomycin C is a methylazirino pyrroloindoledione antineoplastic antibiotic isolated from the bacterium Streptomyces caespitosus and other Streptomyces bacterial species. It targets DNA synthesis and function. The drug candidate is developed based on pegylated liposomal formulation technology.

LipoMedix Pharmaceutical overview

LipoMedix Pharmaceutical (LipoMedix) operates as a developer of drugs for cancer therapy based on liposome delivery. The company’s product Promitil is a chemotherapeutic agent, which is used for treating cancer patients with solid tumors. It conducts clinical and pharmaceutical development of a patented prodrug of mitomycin-C (MMC) and its effective delivery in liposomes to cancer affected organs. The company’s pipeline portfolio offers Promitil (LPMX-1) which has completed Phase 1a study and targeted form of Promitil (LPMX-2) is in preclinical stage. It develops products to treat various types of cancers such as breast, stomach, colon, anal and bladder cancers. LipoMedix is headquartered in Jerusalem, Israel.

Quick View LPMX-1 LOA Data

Report Segments
  • Innovator
Drug Name
  • LPMX-1
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.